CHONDRIAL THERAPEUTICS
Chondrial Therapeutics s a clinical-stage biotechnology company focused on the treatment of rare diseases. It is dedicated to the pursuit of scientific research leading to the treatment for Friedreich’s Ataxia and other mitochondrial diseases.
CHONDRIAL THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2013-01-01
Address:
Bala Cynwyd, Pennsylvania, United States
Country:
United States
Total Employee:
1+
Status:
Active
Contact:
317-370-2234
Email Addresses:
[email protected]
Total Funding:
49.4 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS Amazon Virginia Region Amazon Route 53 Mimecast Ninja Forms
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases.
Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing novel T cell engagers (TriTACs) for the treatment of cancer.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Nivalis Therapeutics
Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.
Larimar Therapeutics
Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases.
Current Employees Featured
Founder
Investors List
Deerfield Capital Management
Deerfield Capital Management investment in Series A - Chondrial Therapeutics
Deerfield
Deerfield investment in Series A - Chondrial Therapeutics
More informations about "Chondrial Therapeutics"
Chondrial Therapeutics- A Company Focused On The Treatment …
In 2016, Chondrial Therapeutics, Inc. was established with funding of $22.6 million primarily from Deerfield Management. This enabled the company to hire a management team, establish a …See details»
FIXING FRIEDREICH’S ATAXIA — Cure FA Foundation
Jun 28, 2017 He joined the board of the leading patient advocacy organization, the Friedreich’s Ataxia Research Alliance (FARA). He launched a biotech …See details»
Chondrial Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Chondrial Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 2 news.See details»
8-K - SEC.gov
May 28, 2020 Agreement and Plan of Merger, dated as of December 17, 2019, by and among the Company (formerly Zafgen, Inc.), Chondrial Therapeutics, Inc., Chondrial Therapeutics …See details»
CHONDRIAL THERAPEUTICS LLC - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for CHONDRIAL THERAPEUTICS LLC of Indianapolis, IN. Get the latest business insights from Dun & Bradstreet.See details»
Chondrial Therapeutics - Contacts, Employees, Board Members, …
Organization. Chondrial Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 3. About. …See details»
Chondrial Therapeutics - VentureRadar
Chondrial Therapeutics was formed to commercialize a proprietary protein replacement platform for mitochondrial diseases. This fusion protein platform was developed by Dr. Mark Payne who …See details»
Chondrial Therapeutics Company Profile - Craft
Chondrial Therapeutics has 5 employees across 2 locations and $23.6 m in total funding,. See insights on Chondrial Therapeutics including office locations, competitors, revenue, financials, …See details»
EX-2.1 - SEC.gov
CHONDRIAL THERAPEUTICS, INC.; and . CHONDRIAL THERAPEUTICS HOLDINGS, LLC . Dated as of December 17, 2019 . SECTION 1. DEFINITIONS AND INTERPRETATIVE …See details»
Chondrial Announces FDA Orphan Drug Designation for CTI-1601, …
Aug 3, 2017 Chondrial Therapeutics is an emerging biotechnology company focused on the treatment of rare mitochondrial diseases. Chondrial's lead compound is CTI-1601, which the …See details»
Potential Friedreich's Ataxia Therapy CTI-1601 Given Orphan Drug...
Aug 17, 2017 “We are very pleased to receive orphan drug designation for CTI-1601. Our team is working to complete all Investigational New Drug (IND) enabling studies so that we can file …See details»
Promising Friedrich’s Ataxia Drug Candidate Gains Support of NIH...
Jan 28, 2016 Chondrial Therapeutics recently announced that further development of its lead drug candidate for the treatment of Friedreich’s ataxia, TAT-Frataxin (TAT-FXN), will be aided …See details»
Chondrial launches to fight rare diseases | C&EN Global Enterprise
Dec 25, 2024 Chondrial Therapeutics has secured up to $23 million in its Series A funding round. Focusing on the treatment of rare mitochondrial diseases, the start-up has licensed a …See details»
Chondrial Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Chondrial Therapeutics, Inc. of Bala Cynwyd, PA. Get the latest business insights from Dun & Bradstreet.See details»
Congratulations to Chondrial Therapeutics, which licenses Indiana ...
Aug 7, 2017 Chondrial Therapeutics Inc. has been granted orphan drug status by the U.S. Food and Drug Administration for CTI-1601, its drug candidate to treat Friedreich’s ataxia. The …See details»
Chondrial Therapeutics and Zafgen Complete Merger and Begin …
May 29, 2020 Chondrial Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the completion of its …See details»
Startup Chondrial in $22.6M Series A, gains new CEO, ataxia med
Feb 6, 2017 Chondrial Therapeutics has secured a near $23 million raise, led by VC Deerfield Management, and has taken on Deerfield’s adviser Carole Ben-Maimon as its new president …See details»
Father Hopes NIH Distinction for Indy-Developed Drug Could Save ...
Mar 31, 2016 Chondrial Therapeutics says Dr. Mark Payne's discoveries could turn a devastating disease into "a very manageable. ... a global organization focused on finding a treatment or cure for the disorder.See details»
Friedreich's Ataxia Therapy Trial Testing CTI-1601 Starts Dosing...
Dec 19, 2019 “CTI-1601 is designed to address the root cause of Friedreich’s ataxia — low levels of frataxin,” said Carole Ben-Maimon, MD, president and CEO of Chondrial …See details»
Nomlabofusp (CTI-1601) - Friedreich's Ataxia Research Alliance
Dec 16, 2024 November 2019: Chondrial Therapeutics begins a first-in-human study of CTI-1601, Single Ascending Dose Study of CTI-1601 versus Placebo in Subjects with FA.As a …See details»